Case Report
Copyright ©The Author(s) 2023.
World J Clin Cases. Mar 6, 2023; 11(7): 1528-1548
Published online Mar 6, 2023. doi: 10.12998/wjcc.v11.i7.1528
Table 2 Characteristics of the reported cases
Characteristic
Patient 7
Patient 8
Patient 9
Patient 10
Patient 11
Age in yr8674657274
SexMaleMaleMaleMaleMale
ComorbiditiesAH, IHD, PE, AF, PM, CKDAH, IHD, AFAHAH, asthmaAH, IHD, diabetes mellitus, AF
Chronic anticoagulant/antiplatelet useAcenocoumarolAcenocoumarolNoRivaroxabanRivaroxaban
Clinical presentationat admissionFever, asthenia, loss of appetiteFever, astheniaFever, astheniaFever, coughFever, asthenia, cough, dyspnea
Duration of illness before admission (days)477127
SpO2 at admission (%)8880757090
Time from admission to bleeding (days)1019121011
Type of bleedRSH, extraperitonealSRHSRHSRHSRH and RSH
Signs and symptoms of bleedAbdominal, back painAbdominal pain, low hemoglobinAbdominal, back painAbdominal painLow hemoglobin, abdominal pain, asthenia, swelling (right)
Hemodynamic instabilityNoYesNoYesNo
Maximum O2 therapy prior to bleed7 L, maskCPAP 85%15 L, mask15 L, mask12 L, mask
Pulmonary changesModerateSevereSevereModerateSevere
Length of hospitalization (days)1731201018
Anticoagulation (prophylactic)NoNoNoNoNo
Anticoagulation therapeuticLMWH 6000 IU, BID; AcenocumarolivHEP, LMWH 6000 IU, BIDLMWH 6000 IU, BIDivHEPivHEP
Antiplatelet therapyNoASA, clopidogrelASAASAASA
SteroidsMethyl-prednisoloneMethyl-prednisoloneMethyl-prednisoloneMethyl-prednisoloneMethyl-prednisolone
Bioproduct units (pRBC/FFP)None5/60/2No4/2
SurgeryYesYes (x 2)NoNoYes
OutcomeDischargedDiedDischargedDiedDischarged